Articles From: ACE Risk Management Receives Innovation Award from Business Insurance Magazine to ACETO Subsidiary, Rising Pharmaceuticals, to Launch the Authorized Generic Version of Covis Pharma S.a.r.l.'s Rilutek(R)


2013/3/7
ACE USA, the U.S.-based retail operation of the ACE Group, today announced that ACE Risk Management, the company’s primary casualty division, has been recognized by Business Insurance Magazine as a recipient in its 2013 Innovation Awards Program.
Sign-up for ACE Risk Management Receives Innovation Award from Business Insurance Magazine investment picks
2013/3/26
ACE USA, the U.S.-based retail operating division of the ACE Group, today announced new executive appointments in its Global Client Executives practice and regional operations in Houston: Pam Humphrey will assume the position of Senior Vice President and Global Client Executive for ACE USA.
Sign-up for ACE USA Announces Executive Appointments in its Global Client Executive Practice and Houston Region investment picks
2013/5/7
ACE USA, the U.S.-based retail operating division of the ACE Group, today announced two new executive appointments in its Foreign Casualty and Custom Casualty divisions: Alexander Wells has been appointed Senior Vice President and National Underwriting Manager of ACE USA’s Custom Casualty Division.
Sign-up for ACE USA Announces Executive Management Appointments within its Underwriting Units in Casualty Lines investment picks
2013/2/4
ACE USA, the U.S.-based retail operations of the ACE Group, today announced the appointment of Andrea T.
Sign-up for ACE USA Appoints Andrea T. Pearson Senior Vice President and Regional Executive Officer, Western Region investment picks
2013/4/8
ACE USA, the U.S.-based retail operations of the ACE Group, through its Medical Risk Group, today announced the introduction of a wide range of physician professional liability insurance products and coverage solutions in support of hospitals and healthcare facilities for their employed physicians, and their owned or affiliated medical groups.
Sign-up for ACE USA Expands Coverage to Address Growing Trend of Hospital and Physician Integration investment picks
2013/4/19
ACE USA, the U.S.-based retail operations of the ACE Group, today announced that its Medical Risk Group has collaborated with Trust Risk Management Services, Inc. (TRMS) to offer an admitted Professional and General Liability policy designed to provide insurance protection to a wide variety of individuals and small groups of six or less allied healthcare providers.
Sign-up for ACE USA Joins With Trust Risk Management Services to Offer Admitted Professional and General Liability Coverage to Individuals and Small Groups of Allied Healthcare Providers investment picks
2013/5/22
ACE USA, the U.S.-based retail operations of the ACE Group, today announced the release of an updated Marine Open Cargo Policy.
Sign-up for ACE USA Updates Marine Open Cargo Policy to Consolidate Coverage in a Single Form investment picks
2013/5/20
ACE USA, the U.S.-based retail operating division of the ACE Group, today announced that Paul Cunney, Vice President, ACE Public Entity Practice Leader will participate in a session discussing privacy and network security exposures and trends with the public sector at the Annual Public Risk Management Association (PRIMA) Conference held in Tampa, FL, on June 2-5, 2013.
Sign-up for ACE USA’s Paul Cunney to Participate in Panel on Privacy & Network Security Exposures & Trends at PRIMA 2013 Annual Conference investment picks
2013/2/12
REDWOOD CITY, Calif.
Sign-up for AcelRx Appoints Adrian Adams to Board of Directors as Chairman investment picks
2013/5/2
- Additional Phase 3 analysis show significantly faster reduction in pain and fewer patients with oxygen desaturation events for Sufentanil NanoTab PCA System than IV PCA with morphine - - Sufentanil NanoTab PCA System remains on track for a Q3 2013 NDA submission - REDWOOD CITY, Calif.
Sign-up for AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting investment picks
2013/2/19
Continued progress towards NDA submission for Sufentanil NanoTab PCA System in Q3 2013 REDWOOD CITY, Calif.
Sign-up for AcelRx Pharmaceuticals Provides Clinical Trial Updates investment picks
2013/5/8
REDWOOD CITY, Calif.
Sign-up for AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results investment picks
2013/3/12
REDWOOD CITY, Calif.
Sign-up for AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results investment picks
2013/5/3
REDWOOD CITY, Calif.
Sign-up for AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013 investment picks
2013/3/7
REDWOOD CITY, Calif.
Sign-up for AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013 investment picks
2013/5/29
REDWOOD CITY, Calif.
Sign-up for AcelRx Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare investment picks
2013/5/16
REDWOOD CITY, Calif.
Sign-up for AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference investment picks
2013/2/27
REDWOOD CITY, Calif.
Sign-up for AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences investment picks
2013/3/4
- Patients experienced significantly greater reduction in pain as measured by SPID-48 vs.
Sign-up for AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients investment picks
2013/4/17
http://media.marketwire.com/attachments/201304/TN-146516_AcerStarTrekBillboard.pdf.jpg Acer and Paramount Pictures Unite to Promote Acer Mobile Products and New 'Star Trek Into Darkness' Movie http://media.marketwire.com/attachments/201206/47720_acer.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1008278&ProfileId=051205&sourceType=1 SAN JOSE, CA --
Sign-up for Acer and Paramount Pictures Unite to Promote Acer Mobile Products and New "Star Trek Into Darkness" Movie investment picks
2013/6/3
TAIPEI ---
Sign-up for Acer Chairman: Windows RT, Running on ARM Chips, Has Not Been Successful investment picks
2013/5/7
TAIPEI --
Sign-up for Acer to Launch Smaller 8-inch Windows Tablet in June investment picks
2013/6/2
TAIPEI --
Sign-up for Acer Unveils Smallest Tablet Running Windows 8 investment picks
2013/6/2
TAIPEI --
Sign-up for Acer Unveils Smallest Tablet to Date Running Windows 8 investment picks
2013/4/24
PORT WASHINGTON, N.Y., April 24, 2013 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET) , a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, announced today that Ronald Gold and David Rosen, former owners of the Rising Pharmaceuticals business acquired by ACETO in December 2010, informed the Company that they intend to pursue other opportunities apart from ACETO upon the expiration of their three-year employment agreements on December 31, 2013.
Sign-up for ACETO Announces Management Transition at Its Rising Pharmaceuticals Subsidiary investment picks
2013/5/9
PORT WASHINGTON, N.Y., May 9, 2013 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET) , a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that its Board of Directors has declared a regular quarterly dividend of $0.055 per common share.
Sign-up for ACETO Board of Directors Declares Quarterly Cash Dividend investment picks
2013/4/26
PORT WASHINGTON, N.Y., April 26, 2013 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET) , a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that it will issue its financial results of operations for its fiscal 2013 third quarter ended March 31, 2013 after the stock market closes on Thursday, May 9, 2013.
Sign-up for ACETO Corporation Schedules Fiscal 2013 Third Quarter Financial Results News Release and Conference Call investment picks
2013/5/9
FISCAL 2013 THIRD QUARTER HIGHLIGHTS (Comparisons to FY 2012 Q3): PORT WASHINGTON, N.Y., May 9, 2013 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET) , a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, announced today results of operations for its fiscal 2013 third quarter and nine months ended March 31, 2013.
Sign-up for ACETO Reports Record Fiscal 2013 Third Quarter Net Sales and Gross Profit investment picks
2013/6/4
PORT WASHINGTON, N.Y., June 4, 2013 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET) , a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals Inc., its finished dosage form generics subsidiary, launched the 0.025% strength of Flunisolide Nasal Solution USP, an FDA approved generic version of Nasalide®. According to IMS Health data, U.S. market sales for Flunisolide, an anti-inflammatory steroid used to treat seasonal and perennial allergies, were approximately $37.3 million for the twelve months ended December 31, 2012.
Sign-up for ACETO Subsidiary, Rising Pharmaceuticals, Launches Generic Version of Nasalide(R) investment picks
2013/6/11
PORT WASHINGTON, N.Y., June 11, 2013 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET) , a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals Inc., its finished dosage form generics subsidiary, will launch the 50mg strength of  Riluzole Tablets, an  FDA approved authorized generic version of Covis Pharma's Rilutek®.   According to IMS Health data, U.S. market sales for Riluzole, which is used to treat Amyotrophic Lateral Sclerosis (ALS), were approximately $64 million for the twelve months ended December 31, 2012.
Sign-up for ACETO Subsidiary, Rising Pharmaceuticals, to Launch the Authorized Generic Version of Covis Pharma S.a.r.l.'s Rilutek(R) investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: ACE Risk Management Receives Innovation Award from Business Insurance Magazine to ACETO Subsidiary, Rising Pharmaceuticals, to Launch the Authorized Generic Version of Covis Pharma S.a.r.l.'s Rilutek(R)
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity